Research on health inequality and genetic disparity in cardiovascular diseases
EMPOWER-1: A Multi-site Clinical Cohort Study to Reduce Health Inequality: Identifying Ethnic Disparities in Treatment Failures for Medicines Prescribed to Treat Diseases That Cause Significant Mortality and Morbidity in the UK Population
This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200000 (estimated) |
| Ages | 6 Years and up |
| Sex | All |
| Sponsor | Future Genetics Limited Academic / other |
| Locations | 1 site (Wolverhampton, West Midlands) |
| Trial ID | NCT03987633 on ClinicalTrials.gov |
What this trial studies
This observational study aims to address health inequality and genetic disparity in the UK by recruiting up to 200,000 patients from diverse ethnic backgrounds, specifically White, African-Caribbean, and South Asian populations. It will analyze biological samples, medical records, and questionnaires to identify treatment failures in various cardiovascular diseases. The study seeks to provide real-world evidence on disease prevalence and inform clinical practices to improve health outcomes for underrepresented populations. By pooling data from multiple NHS sites, the research will ensure a meaningful representation of different ethnicities.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with atrial fibrillation, coronary heart disease, heart failure, hypertension, or other cardiovascular diseases, particularly from the specified ethnic groups.
Not a fit: Patients who are not registered with the NHS or lack the capacity to provide consent may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and health outcomes for diverse patient populations suffering from cardiovascular diseases.
How similar studies have performed: While the focus on health inequality and genetic disparity is increasingly recognized, this specific approach of large-scale, multi-ethnic cohort analysis is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients or their relative/family member is diagnosed with the illness being investigated by this study. 2. All NHS patients that are associated with a participating study site, but do not fall under the first bullet point above, may participate with a view that they may potentially contribute to a case control population in the research study. 3. Subjects agree to: 1. Gift biological samples, i.e. saliva. Where practical, blood or other biological samples may be voluntarily provided by the patient. 2. Provide Consent for access to medical records. 3. Complete disease specific, quality of life, and study associated questionnaires. Exclusion Criteria: 1. Patient does not provide a valid consent for study participation. 2. Patient is not registered with the NHS for care. 3. Patient lacking capacity, who does not have an illness that is being specifically investigated by this clinical research study. 4. Person lacks capacity and where the personal consultee has not advised that the Person may enrol, in accordance with the Mental Health Act 2005.
Where this trial is running
Wolverhampton, West Midlands
- Future Genetics, The Science Centre, Wolverhampton Science Park — Wolverhampton, West Midlands, United Kingdom (Recruiting)
Study contacts
- Study coordinator: Dr Mohammed Kamran
- Email: director@futuregenetics.co.uk
- Phone: 00441216673007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.